ArticleInvestigative ophthalmology & visual science2026
YTHDF1-Mediated m6A Modification of NREP Promotes Corneal Fibrosis via TGF-β-Smad Signaling.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Corneal fibrosis ranks among the foremost drivers of global vision loss and blindness, yet therapeutic options remain scarce. This study investigated neuronal regeneration-related protein (NREP), which is recognized by the N6-methyladenosine (m6A) modification reader protein YTH domain family member 1 (YTHDF1), in promoting corneal fibrosis in keratocytes. Methods: In vivo, a standardized alkali burn model was created in C57BL/6 mice with corneas harvested on days 7, 14, and 21. Fibrosis, NREP, and m6A modifications were estimated using slit-lamp, real-time quantitative polymerase chain reaction (RT-qPCR), and western blotting. In vitro, isolated keratocytes were treated with TGF-β1. Small interfering RNA (si-RNA) was used to downregulate NREP and YTHDF1 expression in keratocytes. SKLB-Y13 was used to specifically inhibit YTHDF1. Cell proliferation, migration, and alpha-smooth muscle actin (α-SMA) expression were assessed using CCK-8 assays, scratch-wound assays, flow cytometry, immunofluorescence, and liquid chromatography-mass spectrometry. Following keratocyte fibrosis induction using 10% fetal bovine serum, the indicators were evaluated. Results: Corneal fibrosis peaked on day 14 post-injury, coinciding with increased NREP protein levels versus controls. NREP knockdown reduced keratocyte proliferation and migration and abolished TGF-β1-induced α-SMA expression. YTHDF1 depletion phenocopied these effects and lowered NREP protein levels, suggesting translational control. Sequence-based RNA adenosine methylation site predictor (SRAMP) revealed enriched m6A modifications in NREP mRNA. YTHDF1 deficiency reduced NREP translation and impaired TGF-β-Smad signaling, leading to decreased keratocyte proliferation and motility and impaired fibroblast-to-myofibroblast differentiation. Conclusions: YTHDF1 promotes corneal fibrosis through m6A-dependent enhancement of NREP translation, potentiating TGF-β-Smad and myofibroblast transdifferentiation, and thus may serve as a therapeutic target for fibrotic corneal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.